(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 October 2025 (09.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/212708 A2

(51) International Patent Classification:
A61K 47/68 (2017.01) *C07K 16/28* (2006.01)

(21) International Application Number:
PCT/US2025/022623

(22) International Filing Date:
01 April 2025 (01.04.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/574,108 03 April 2024 (03.04.2024) US

(71) Applicant: **AVIDITY BIOSCIENCES, INC.** [US/US]; 10578 Science Center Drive, Suite 125, San Diego, California 92121 (US).

(72) Inventors: **ALBIN, Tyler**; 10578 Science Center Drive, Suite 125, San Diego, California 92121 (US). **COCHRAN, Michael Caramian**; 10578 Science Center Drive, Suite 125, San Diego, California 92121 (US). **DOPPALAPUDI, Venkata Ramana**; 10578 Science Center Drive, Suite 125, San Diego, California 92121 (US). **ETXANIZ IRIGOIEN, Usue**; 10578 Science Center Drive, Suite 125, San Diego, California 92121 (US). **KARAMANLIDIS, Georgios**; 10578 Science Center Drive, Suite 125, San Diego, California 92121 (US). **MARKS, Isaac**; 10578 Science Center Drive, Suite 125, San Diego, California 92121 (US). **SVENSSON, Sven Ove Kristoffer**; 10578 Science Center Drive, Suite 125, San Diego, California 92121 (US).

(74) Agent: **SHIN, Minyoung** et al.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

(54) Title: ANTIBODY-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING DMD EXON 50 SKIPPING




FIG. 1

(57) Abstract: Disclosed herein are antibody-oligonucleotide conjugates and pharmaceutical compositions comprising the antibody-oligonucleotide conjugates that induce an alteration in an incorrectly spliced dystrophin mRNA transcript to induce DMD exon 50 skipping. Also described herein include methods for treating muscle dystrophy including Duchenne muscular dystrophy by administering antibody-oligonucleotide conjugates or a pharmaceutical composition comprising the antibody-oligonucleotide conjugates that induce an alteration in an incorrectly spliced dystrophin mRNA transcript to induce DMD exon 50 skipping.

[Continued on next page]

WO 2025/212708 A2

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*